Lina Huerta-Saenz

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Growth hormone (GH) treatment of idiopathic short stature (ISS), defined as height <-2.25 standard deviations (SD), is approved by U.S. FDA. This study determined the gender-specific prevalence of height <-2.25 SD in a pediatric primary care population, and compared it to demographics of U.S. pediatric GH recipients. Data were extracted from health records(More)
  • 1